Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I–II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here is a complete pathological response seen in a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Willett, Christopher G, Duda, Dan G, di Tomaso, Emmanuelle, Boucher, Yves, Czito, Brian G, Vujaskovic, Zeljko, Vlahovic, Gordana, Bendell, Johanna, Cohen, Kenneth S, Hurwitz, Herbert I, Bentley, Rex, Lauwers, Gregory Y, Poleski, Martin, Wong, Terence Z, Paulson, Erik, Ludwig, Kirk A, Jain, Rakesh K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686127/
https://ncbi.nlm.nih.gov/pubmed/17464339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncponc0813
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller